NCT05129644 - Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2009

Primary Completion Date

June 26, 2010

Study Completion Date

June 26, 2010

Conditions

Healthy Volunteers

Interventions

DRUG

P1101 (24 mcg)

P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 24 mcg subcutaneously.

DRUG

P1101 (48 mcg)

P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 48 mcg subcutaneously.

DRUG

P1101 (90 mcg)

P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 90 mcg subcutaneously.

DRUG

P1101 (180 mcg)

P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 180 mcg subcutaneously.

DRUG

P1101 (225 mcg)

P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 225 mcg subcutaneously.

DRUG

P1101 (270 mcg)

P1101 solution for injection, 180 mcg/mL, 1.2 mL/vial;Dose/subject: 270 mcg subcutaneously.

DRUG

Pegasys

Pegasys for injection, 180 mcg/mL, 1.0 mL/vial, Dose/subject: 180 mcg subcutaneously.

Trial Locations (1)

Anapharm, Québec